Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday

Trevi Therapeutics (NASDAQ:TRVI) is expected to be posting its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Trevi Therapeutics to post earnings of ($0.10) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 17, 2026 at 4:30 PM ET.

Trevi Therapeutics Stock Down 1.7%

Shares of NASDAQ TRVI opened at $11.01 on Friday. The stock’s 50-day simple moving average is $11.17 and its two-hundred day simple moving average is $10.85. Trevi Therapeutics has a twelve month low of $4.85 and a twelve month high of $14.39. The firm has a market capitalization of $1.41 billion, a P/E ratio of -29.76 and a beta of 0.94.

Institutional Investors Weigh In On Trevi Therapeutics

A number of hedge funds have recently made changes to their positions in TRVI. Russell Investments Group Ltd. boosted its stake in shares of Trevi Therapeutics by 194.5% in the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company’s stock valued at $25,000 after purchasing an additional 2,996 shares in the last quarter. Strs Ohio purchased a new position in Trevi Therapeutics in the 1st quarter worth $52,000. Rafferty Asset Management LLC purchased a new position in Trevi Therapeutics in the 2nd quarter worth $60,000. Creative Planning lifted its stake in Trevi Therapeutics by 17.5% in the second quarter. Creative Planning now owns 20,247 shares of the company’s stock worth $111,000 after purchasing an additional 3,016 shares during the last quarter. Finally, Abel Hall LLC bought a new stake in Trevi Therapeutics in the fourth quarter worth $128,000. 95.76% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

TRVI has been the topic of several research analyst reports. Leerink Partners upped their price objective on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $19.00 target price on shares of Trevi Therapeutics in a research report on Monday, March 9th. B. Riley Financial raised shares of Trevi Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Trevi Therapeutics in a report on Monday, March 9th. Finally, Oppenheimer restated an “outperform” rating on shares of Trevi Therapeutics in a research report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.10.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.